Oxford Ledge
Search
No licensed closing price on file for GPCR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:23 UTC.
The company is a clinical-stage biopharmaceutical firm developing oral small molecule drugs to treat chronic diseases by targeting G-protein coupled receptors, which regulate many physiological processes and are the focus of approximately one in every three marketed medicines. Its lead product candidate is aleniglipron, a GLP-1 receptor agonist in five ongoing clinical studies for obesity and related conditions, and the company also has amylin receptor agonists and other candidates in earlier development stages.
Summarized from Structure Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for GPCR and 5,000+ tickers.
Create a free account — keep GPCRGET /api/data?ticker=GPCR
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt